Further analysis showed that the 5-year overall survival rate of GC patients with high BCAT2 expression was significantly higher than that of GC patients with low BCAT2 expression (46.1% vs. 53.9%; p < 0.01, Figure 5D). This evidence concerns the gene BCAT2 and gastric cancer.